Strong Cyp3a4 And P-Glycoprotein Inducers has 6 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Everolimus, Neratinib, Lenacapavir Sodium. Patients taking Strong Cyp3a4 And P-Glycoprotein Inducers should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Contraindicated
- 2
- Major
- 4
Contraindicated (2)
- Strong Cyp3a4 And P-Glycoprotein Inducers + Everolimus— Avoid concomitant use of P-gp and strong CYP3A4 inhibitors with everolimus due to increased drug exposure.
- Strong Cyp3a4 And P-Glycoprotein Inducers + Neratinib— Concomitant use may increase neratinib Cmax and AUC, increasing risk of NERLYNX toxicity. Avoid concomitant use.
Major (4)
- Strong Cyp3a4 And P-Glycoprotein Inducers + Lenacapavir Sodium— Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase lenacapavir plasma concentrations.
- Strong Cyp3a4 And P-Glycoprotein Inducers + Paliperidone Palmitate— Concomitant use may decrease paliperidone exposure. Avoid during dosing interval if possible; consider paliperidone exte…
- Strong Cyp3a4 And P-Glycoprotein Inducers + Relugolix— Co-administration decreases relugolix exposure, which may reduce therapeutic effects. If unavoidable, increase ORGOVYX d…
- Strong Cyp3a4 And P-Glycoprotein Inducers + Relugolix, Estradiol Hemihydrate, And Norethindrone Acetate— Decreases AUC and Cmax of relugolix, estradiol, and/or norethindrone, may decrease therapeutic effects of MYFEMBREE. Avo…